查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138365

全球瘙癢治療市場-2022-2029

Global Pruritus Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球瘙癢藥物市場是由影響瘙癢發病率的皮膚病發病率增加以及對治療此類病症的適當診斷和治療劑的需求不斷增加推動的。由於多種因素，該市場正在增長。新的瘙癢治療藥物的開發正在推動全球市場的增長。

針對各類瘙癢症的新型靶向療法的開發正在推動全球瘙癢症藥物市場的增長。例如，這些其他新療法和 Duplimab 的開發，一種特異性靶向參與炎症反應進展的白細胞介素 4 受體的單克隆抗體，如 Crisaborole 2% 軟膏，是 Janus 激□抑製劑。包括代理在內的外用藥物主要主要市場參與者的管道。此外，不同監管機構對這些新開發的療法的批准將推動市場增長。例如，2022 年 6 月，賽諾菲開發的 Dupixent（duplimab）成為美國食品藥品監督管理局（Food and Drug Administration）驗證的第一個用於治療 6 個月至 5 歲兒童中重度皮炎的生物製劑。公式。此類市場事件和新治療劑的開發正在推動全球市場的增長。

然而，對於治療瘙癢症的藥物認知度低以及藥物副作用的發生，將成為治療瘙癢症市場增長的障礙。

然而，對於治療瘙癢症的藥物認知度低，以及與治療瘙癢症藥物相關的副作用的發生阻礙了市場的增長。

行業分析

《瘙癢症藥物市場報告》根據波特五力、研發、流行病學、監管分析、定價分析和管道分析等各種行業因素對市場進行了深入分析。

COVID-19 影響分析

美國接觸性皮炎協會報告說，COVID-19 大流行增加了接觸性皮炎病例的數量。在 COVID-19 期間，CDC 建議使用肥皂、清潔劑和含酒精的洗手液反復進行手部消毒，這會改變皮膚屏障的完整性和完整性功能，從而增加患皮炎的風險。此外，在 COVID-19 爆發期間，建議醫護人員使用個人防護套件，增加了接觸性皮炎的醫護人員數量，對瘙癢症市場產生積極影響。我在這裡。

全球瘙癢治療市場報告將提供對大約 40 多個市場數據表、45 多個數字和 200 多頁（大約）的訪問。

內容

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 調查與研發
      • 提高認識
      • 市場策略
    • 限制因素
      • 治療的副作用
      • 嚴格的監管機構
    • 機會
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 流行病學分析
  • 研發
  • 管道分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按疾病類型

  • 特應性皮炎
  • 過敏性接觸性皮炎
  • 蕁麻疹
  • 其他

第 8 章給藥途徑

  • 口服劑
  • 注入
  • 外部代理

第 9 章按治療類別

    • 抗組胺藥
  • 腎上腺皮質類固醇
  • 抗刺激劑
  • 局部麻醉劑
  • 鈣調磷酸□抑製劑
  • 免疫抑製劑
  • 其他

第十章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 13 章公司簡介

  • Leo Pharma
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Bausch Health
  • Astellas Pharma U.S.Inc.
  • Pfizer Inc.
  • Mylan
  • Bayer AG
  • Allergen
  • Sanofi
  • Eli Lilly
  • Sandoz Inc.

第14章 DataM

簡介目錄
Product Code: DMPH2160

Market Overview

Pruritus Therapeutics Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 6.1% during the forecast period (2022-2029).

Pruritus, or itch, is commonly associated with primary skin disorders such as atopic dermatitis, urticaria, psoriasis, Masto cytosis, and dermatitis herpetiformis, among others. A typical itching generally forms the diagnosis of a major dermatologic disorder. Several skin diseases related to pruritus, such as renal pruritus, hematologic pruritus, cholestatic pruritus, idiopathic generalized pruritus, pruritus related to malignancy and endocrine pruritus. Increased ions such as calcium, phosphate, and magnesium are found in pruritic patients' skin. Severe pruritus leads to scratching that causes secondary skin problems such as eczematisation, dryness, infection, excoriation, Contact allergy, and lichenification.

Market Dynamics

The global pruritus therapeutics market is growing due to several factors, such as the increasing incidence of dermatological disorders influencing the occurrence of pruritus and the growing demand for proper diagnostics and therapeutics to treat such medical conditions. The development of new therapeutics for pruritus is forcing global market growth.

The development of new targeted therapies for different pruritus is driving the growth of the global pruritus therapeutics market. For instance, the development of Duplimab, which is a monoclonal antibody that specifically targets interleukin-4 receptors that are involved in the progression of the inflammatory response with these other novel therapeutics, for example, Crisaborole 2% ointment and others are in the pipeline of major key market players for topical medication including the Janus kinase inhibitors. Furthermore, the approval of these newly developed therapeutics by different regulatory bodies propels the market towards growth. For instance, in June 2022, Dupixent (Duplimab), developed by Sanofi, is the first biologics medicine validated by the United States Food and Drug Administration to treat moderate to severe dermatitis in children aged 6 months to 5 years. These market events and the development of new therapeutics are fueling the market growth globally.

The lack of awareness and incidences of drug side effects will become a hurdle in the pruritus therapeutics market growth.

However, the lack of awareness towards therapeutics for pruritus and the associated side effects associated with pruritus therapeutics hinder the market's growth.

Industry analysis.

The pruritus therapeutics market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory analysis, pricing analysis and pipeline analysis, Etc.

COVID-19 Impact Analysis

The American Contact Dermatitis Society informed that the covid-19 pandemic had increased the number of contact dermatitis cases. Amidst covid-19, the CDC recommended repetitive hand hygiene with soaps, detergents, and hand sanitization through alcohol-containing hand sanitizers, which lead to the integrity and integrity function alteration in the skin barrier, raising the risk of dermatitis. Also, during the covid-19 outbreak, healthcare professionals were suggested to employ personal protective kits, which have caused a rise in the number of healthcare professionals experiencing contact dermatitis, positively impacting the pruritus therapeutics market.

Segment Analysis

The corticosteroids will dominate the pruritus therapeutics market during the forecast period (2022-2029).

The corticosteroids segment accounted for the highest market share in 2021 and is expected to dominate the Pruritus therapeutics market during the forecast period (2022-2029) since corticosteroids are widely used as the first line of treatment for acute pruritus associated with moderate to severe inflammatory skin diseases, such as AD, allergic contact dermatitis, psoriasis and lichen planus. Corticosteroids are activated glucocorticoid receptors that inhibit cytokine activation, thereby decreasing local inflammation and indirectly controlling pruritus. More than 30 different topical steroid formulations are available in the United States, and these are prepared on different bases (e.g., solution, lotion, cream or ointment). Topical corticosteroids range in potency from low (Class VII) to high or ultra-potent (Class I). It is generally accepted that the clinical efficacy to treat inflammation, and indirectly pruritus, correlates with steroid potency.

Geographical Analysis

North America is subjugating the pruritus therapeutics market.

North America dominated the pruritus therapeutics market in 2021. It is estimated that North America will command the global pruritus therapeutics market during the forecast period (2022-2029) since most key market players are headquartered in North America and are involved in developing new drug therapies such as biologics. Examples are Bausch Health, Astellas Pharma U.S.Inc., Pfizer Inc., Mylan, Bayer AG, Allergen, Eli Lilly, and many more. Also, owing to the health care sector developments, organizations and societies are actively looking out for pruritus and government initiatives for spreading awareness about pruritus. For instance, founded in 1989, the American Contact Dermatitis Society is focused on pruritus with over 2,500 healthcare professionals in the field of pruritus and related skin inflammatory diseases. Also, the North American Contact Dermatitis Group is helping thousands of people make informed, evidence-based skin care decisions. These facts show that the North American region will dominate the pruritus therapeutics market over the forecast period.

Competitive Landscape

The pruritus therapeutics market is competitive, with few major players competing to gain market share. Some major players in the global pruritus therapeutics market include Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd, Pfizer, Sanofi, GlaxoSmithKline, Merck, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the global Pruritus Therapeutics market's growth. For instance, in January 2022, Pfizer acquired U.S.FDA approval for its Cibinqo (Adrocitinib), an oral once-a-day Janus kinase inhibitor for treating adults suffering from dermatitis. Also, in April 2022, Leo Pharma presented its interim long-term efficacy data for Adbry (Tralokinumab-ldrm). Such incidences create a competitive environment in the Pruritus Therapeutics market.

Leo Pharma

Overview

Leo Pharma is a leading company in the dermatology market, founded in 1908 and headquartered in Denmark. It is primarily focused on research and development to advance the science of dermatology.

Product Portfolio

Leo Pharma's dermatological product portfolio has Adtralza, Dovobet, Dovonex, Enstilar, Finacea, Kyntheum, Protopic, Skinoren, Fucidin, and Fucibet.

The global pruritus therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Research and Development
      • 4.1.1.2. Increased Awareness
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. Treatment Side Effects
      • 4.1.2.2. Stringent Regulatory Bodies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiological Analysis
  • 5.3. Research and Developments
  • 5.4. Pipeline Analysis
  • 5.5. Supply Chain Analysis
  • 5.6. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
    • 7.1.2. Market Attractiveness Index, By Disease Type Segment
  • 7.2. Atopic Dermatitis
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Allergic Contact Dermatitis
  • 7.4. Urticaria
  • 7.5. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Oral
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Injectables
  • 8.4. Topical

9. By Drug Class

    • 9.1.1. Introduction
    • 9.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    • 9.1.3. Market Attractiveness Index, By Drug Class Segment
    • 9.1.4. Antihistaminic
    • 9.1.5. Introduction
    • 9.1.6. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.2. Corticosteroids
  • 9.3. Counterirritants
  • 9.4. Local Anesthetics
  • 9.5. Calcineurin Inhibitors
  • 9.6. Immunosuppressant
  • 9.7. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 10.2. Hospital Pharmacy
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacy
  • 10.4. Online Pharmacy

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Leo Pharma
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Bausch Health
  • 13.3. Astellas Pharma U.S.Inc.
  • 13.4. Pfizer Inc.
  • 13.5. Mylan
  • 13.6. Bayer AG
  • 13.7. Allergen
  • 13.8. Sanofi
  • 13.9. Eli Lilly
  • 13.10. Sandoz Inc.

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact